Predictive value of combined analysis of pro-NPY and ERG in localized prostate cancer

Gitte Kristensen; Martin Andreas Røder; Kasper Drimer Berg; Johanna Elversang; Diego Iglesias-Gato; José Moreira; Birgitte Grønkær Toft; Klaus Brasso

doi:10.1111/apm.12886

Predictive value of combined analysis of pro-NPY and ERG in localized prostate cancer

Gitte Kristensen^*, Martin Andreas Røder, Kasper Drimer Berg, Johanna Elversang, Diego Iglesias-Gato, José Moreira, Birgitte Grønkær Toft, Klaus Brasso

^*Corresponding author af dette arbejde

Institut for Klinisk Medicin

7 Citationer (Scopus)

Abstract

This study aimed to investigate if combined analysis of pro-Neuropeptide Y (NPY) and ERG expression in tumor tissue are associated with biochemical failure (BF), castration-based treatment, castration-resistant prostate cancer (CRPC), and prostate cancer (PCa)-specific death for men undergoing radical prostatectomy (RP) for PCa. This study included 315 patients, who underwent RP from 2002 to 2005. Both pro-NPY and ERG expression were analyzed using immunohistochemistry and were scored as low or high and negative or positive, respectively. Risk of BF, castration-based treatment, CRPC, and PCa-specific death were analyzed with multiple cause-specific Cox regression analyses and stratified cumulative incidences using competing risk assessment. Median follow-up was 13.0 years (95% CI: 12.7–13.2). In total, 85.7% were pro-NPY high and 14.3% were pro-NPY low. The combined analyses of pro-NPY and ERG expression was not associated with risk of BF (p = 0.7), castration-based treatment (p = 0.8), CRPC (p = 0.4) or PCa-specific death (p = 0.5). In the multiple cause-specific Cox regression analysis, pro-NPY high and ERG positivity was not associated with BF (HR: 1.02; 95% CI 0.6–1.7; p = 0.94). In conclusion the combination of pro-NPY and ERG expression did not show association with risk of BF, castration-based treatment, CRPC, and PCa-specific death following RP.

Originalsprog	Engelsk
Tidsskrift	A P M I S. Acta Pathologica, Microbiologica et Immunologica Scandinavica
Vol/bind	126
Udgave nummer	10
Sider (fra-til)	804-813
ISSN	0903-4641
DOI	https://doi.org/10.1111/apm.12886
Status	Udgivet - okt. 2018

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

10.1111/apm.12886

Citationsformater

@article{8be3375a0e16451788d4c67994dd4e6b,

title = "Predictive value of combined analysis of pro-NPY and ERG in localized prostate cancer",

abstract = "This study aimed to investigate if combined analysis of pro-Neuropeptide Y (NPY) and ERG expression in tumor tissue are associated with biochemical failure (BF), castration-based treatment, castration-resistant prostate cancer (CRPC), and prostate cancer (PCa)-specific death for men undergoing radical prostatectomy (RP) for PCa. This study included 315 patients, who underwent RP from 2002 to 2005. Both pro-NPY and ERG expression were analyzed using immunohistochemistry and were scored as low or high and negative or positive, respectively. Risk of BF, castration-based treatment, CRPC, and PCa-specific death were analyzed with multiple cause-specific Cox regression analyses and stratified cumulative incidences using competing risk assessment. Median follow-up was 13.0 years (95% CI: 12.7–13.2). In total, 85.7% were pro-NPY high and 14.3% were pro-NPY low. The combined analyses of pro-NPY and ERG expression was not associated with risk of BF (p = 0.7), castration-based treatment (p = 0.8), CRPC (p = 0.4) or PCa-specific death (p = 0.5). In the multiple cause-specific Cox regression analysis, pro-NPY high and ERG positivity was not associated with BF (HR: 1.02; 95% CI 0.6–1.7; p = 0.94). In conclusion the combination of pro-NPY and ERG expression did not show association with risk of BF, castration-based treatment, CRPC, and PCa-specific death following RP.",

keywords = "ERG, predictive biomarkers, pro-NPY, prostate cancer, radical prostatectomy",

author = "Gitte Kristensen and R{\o}der, {Martin Andreas} and Berg, {Kasper Drimer} and Johanna Elversang and Diego Iglesias-Gato and Jos{\'e} Moreira and Toft, {Birgitte Gr{\o}nk{\ae}r} and Klaus Brasso",

year = "2018",

month = oct,

doi = "10.1111/apm.12886",

language = "English",

volume = "126",

pages = "804--813",

journal = "APMIS. Supplementum",

issn = "0903-465X",

publisher = "Wiley Online",

number = "10",

}

TY - JOUR

T1 - Predictive value of combined analysis of pro-NPY and ERG in localized prostate cancer

AU - Kristensen, Gitte

AU - Røder, Martin Andreas

AU - Berg, Kasper Drimer

AU - Elversang, Johanna

AU - Iglesias-Gato, Diego

AU - Moreira, José

AU - Toft, Birgitte Grønkær

AU - Brasso, Klaus

PY - 2018/10

Y1 - 2018/10

N2 - This study aimed to investigate if combined analysis of pro-Neuropeptide Y (NPY) and ERG expression in tumor tissue are associated with biochemical failure (BF), castration-based treatment, castration-resistant prostate cancer (CRPC), and prostate cancer (PCa)-specific death for men undergoing radical prostatectomy (RP) for PCa. This study included 315 patients, who underwent RP from 2002 to 2005. Both pro-NPY and ERG expression were analyzed using immunohistochemistry and were scored as low or high and negative or positive, respectively. Risk of BF, castration-based treatment, CRPC, and PCa-specific death were analyzed with multiple cause-specific Cox regression analyses and stratified cumulative incidences using competing risk assessment. Median follow-up was 13.0 years (95% CI: 12.7–13.2). In total, 85.7% were pro-NPY high and 14.3% were pro-NPY low. The combined analyses of pro-NPY and ERG expression was not associated with risk of BF (p = 0.7), castration-based treatment (p = 0.8), CRPC (p = 0.4) or PCa-specific death (p = 0.5). In the multiple cause-specific Cox regression analysis, pro-NPY high and ERG positivity was not associated with BF (HR: 1.02; 95% CI 0.6–1.7; p = 0.94). In conclusion the combination of pro-NPY and ERG expression did not show association with risk of BF, castration-based treatment, CRPC, and PCa-specific death following RP.

AB - This study aimed to investigate if combined analysis of pro-Neuropeptide Y (NPY) and ERG expression in tumor tissue are associated with biochemical failure (BF), castration-based treatment, castration-resistant prostate cancer (CRPC), and prostate cancer (PCa)-specific death for men undergoing radical prostatectomy (RP) for PCa. This study included 315 patients, who underwent RP from 2002 to 2005. Both pro-NPY and ERG expression were analyzed using immunohistochemistry and were scored as low or high and negative or positive, respectively. Risk of BF, castration-based treatment, CRPC, and PCa-specific death were analyzed with multiple cause-specific Cox regression analyses and stratified cumulative incidences using competing risk assessment. Median follow-up was 13.0 years (95% CI: 12.7–13.2). In total, 85.7% were pro-NPY high and 14.3% were pro-NPY low. The combined analyses of pro-NPY and ERG expression was not associated with risk of BF (p = 0.7), castration-based treatment (p = 0.8), CRPC (p = 0.4) or PCa-specific death (p = 0.5). In the multiple cause-specific Cox regression analysis, pro-NPY high and ERG positivity was not associated with BF (HR: 1.02; 95% CI 0.6–1.7; p = 0.94). In conclusion the combination of pro-NPY and ERG expression did not show association with risk of BF, castration-based treatment, CRPC, and PCa-specific death following RP.

KW - ERG

KW - predictive biomarkers

KW - pro-NPY

KW - prostate cancer

KW - radical prostatectomy

U2 - 10.1111/apm.12886

DO - 10.1111/apm.12886

M3 - Journal article

C2 - 30191621

AN - SCOPUS:85052934413

SN - 0903-465X

VL - 126

SP - 804

EP - 813

JO - APMIS. Supplementum

JF - APMIS. Supplementum

IS - 10

ER -

Predictive value of combined analysis of pro-NPY and ERG in localized prostate cancer

Abstract

FN’s Verdensmål

Adgang til dokumentet

Fingeraftryk

Citationsformater